• SGC-CBP30 for CREBBP/EP300 Epigenetic Studies

  2026-08-18

  SGC-CBP30 is a selective CREBBP/EP300 bromodomain inhibitor for connecting coactivator biology with transcription, chromatin occupancy, and cancer phenotypes. This workflow shows how to use it in benchmark HeLa and RKO assays and how to cautiously extend the approach to super-enhancer-driven lung adenocarcinoma research.

• Calpain Inhibitor I, ALLN: Practical Protocol

  2026-08-18

  Calpain Inhibitor I, ALLN (SKU A2602) is a research reagent for probing calpain- and cathepsin-associated proteolysis in apoptosis, inflammation, and ischemia-reperfusion workflows. It should be handled as a DMSO-based experimental inhibitor and not used for diagnostic, therapeutic, or medical applications.

• Müller Cell PEDF in Angiopoietin Retinal Survival

  2026-08-17

  Younis and colleagues show that angiopoietin-1 and angiopoietin-2 regulate retinal neuron survival indirectly through Müller cell Tie-2/PI3K/Akt signaling and pigment epithelium-derived factor production. The work defines a neurovascular signaling circuit that connects angiopoietin balance, hypoxic stress, PEDF/PEDF-R activity, and neuronal viability.

• nor-NOHA in Arginase and AML Research

  2026-08-17

  nor-NOHA acetate gives researchers a reversible way to interrogate arginine competition between arginase and nitric oxide synthase. This article translates that mechanism into HepG2, AML immune-metabolism, and endothelial assays while separating established findings from testable extensions.

• Nutlin-3a: MDM2 Inhibitor Mechanism & Uses

  2026-08-16

  Nutlin-3a is a small-molecule MDM2 inhibitor that occupies the TP53-binding pocket of MDM2 and prevents p53 degradation. The compound is a research tool for p53 pathway activation, cell cycle arrest, apoptosis induction, and cancer research, but its activity remains dependent on cellular genotype and experimental context.

• Sodium Ascorbate for ROS Cancer Assays

  2026-08-15

  Sodium Ascorbate provides a practical way to study ROS-linked tumor-cell injury, proliferation loss, and motility changes in controlled cancer models. This guide emphasizes solvent-aware preparation, time-course design, orthogonal validation, and careful separation of glioblastoma evidence from emerging immunotherapy-biomarker questions.

• Drosophila Keap1 Nuclear Condensates Under Oxidative Stress

  2026-08-14

  The reference study identifies oxidative stress–responsive nuclear condensates as a previously unrecognized organizational state of Drosophila Keap1. Domain-deletion, FRAP, and in vitro reconstitution experiments implicate the C-terminal disordered regions in condensate formation, while the Kelch domain acts as an inhibitory regulator.

• Nocodazole: From Mitotic Arrest to Translation

  2026-08-14

  Nocodazole is more than a mitotic-arrest reagent: it is a reversible microtubule perturbation tool that can help translational researchers connect spindle state, cell-cycle progression, and cap-dependent translation. This article presents a mechanism-led framework for experimental design, assay validation, and anticancer drug evaluation while defining the boundaries of what Nocodazole can and cannot establish.

• CCG-1423: RhoA Signaling at the Barrier

  2026-08-13

  CCG-1423 offers a mechanistically distinct way to interrogate RhoA transcriptional signaling, MRTF-A nuclear import, metastasis, apoptosis, and potentially virus-associated barrier remodeling. This thought-leadership guide connects the compound’s established cancer research utility with the RhoA/ROCK1/MLC2 mechanism reported in canine parvovirus infection while clearly separating evidence from translational hypothesis.

• PD 0332991 (Palbociclib HCl): Mechanism & Use

  2026-08-13

  PD 0332991, also called Palbociclib HCl, is a selective CDK4/6 inhibitor that suppresses Rb phosphorylation and promotes G1 arrest in Rb-positive research models. Product-level potency, cell-cycle, xenograft, formulation, and storage data support its use as a research tool rather than as a universal anticancer treatment.

• Nebivolol hydrochloride Research Workflows

  2026-08-12

  Build cleaner β1-adrenergic receptor experiments with a highly selective β1-adrenoceptor antagonist, while avoiding accidental interpretation as an mTOR inhibitor. This guide combines DMSO handling, receptor-signaling workflows, orthogonal yeast validation, and troubleshooting for cardiovascular pharmacology research.

• CXCR4 Theranostics in Lymphoma: Imaging to Therapy

  2026-08-12

  This 2026 review presents CXCR4 as a theranostic target in lymphoma, linking receptor biology with PET/SPECT imaging, targeted radioligand therapy, antagonists, and antibodies. Its main contribution is an integrated framework for selecting CXCR4-directed agents while recognizing physiological uptake, variable receptor expression, and compensatory CXCR7 signaling as barriers to clinical translation.

• RCN2, PPP2CA, and Cisplatin Resistance in ESCC

  2026-08-11

  The reference study identifies RCN2 as a driver of esophageal squamous cell carcinoma metastasis and cisplatin resistance through UBR5-dependent ubiquitination and degradation of PPP2CA. Its integrated molecular, cellular, and animal experiments position the RCN2–PPP2CA–PI3K-AKT axis as a mechanistic target for future ESCC research, while also defining important questions about pathway-specific therapeutic intervention.

• Metagenomic Discovery of Potent Cas9 Inhibitors

  2026-08-11

  Forsberg and colleagues developed a phenotype-based functional metagenomic selection that uncovered ten DNA fragments encoding inhibitors of Streptococcus pyogenes Cas9. The study identified AcrIIA11 as a potent inhibitor active in bacterial and human-cell contexts, demonstrating that microbiome-derived anti-CRISPR proteins can be discovered without relying on recognizable sequence signatures.

• Pitavastatin (NK-104): In Vitro Workflow Guide

  2026-08-10

  Pitavastatin (NK-104, SKU B1124) is a high-purity HMG-CoA reductase inhibitor for controlled cell-based or biochemical studies of cholesterol biosynthesis. This guide translates the product dossier into a reproducible in vitro workflow; it should not be used as evidence for clinical use, animal dosing, or mechanism transfer across models without additional validation.

16816 records 1/1122 page Next 12345 下5页 Last page